The U.S. Pharmacopeia identifies 15 priorities for the next five years.

In May 2020, the U.S. Pharmacopeia Commission (USPC) held a web-based meeting to review its central role in advancing public health and to evaluate its response to the urgent needs of the COVID-19 crisis.
also adopted 15 resolutions aimed at setting strategic priorities for the next five-year cycle.
usP meetings are held every five years, bringing together representatives of voting member organizations (there are nearly 500 existing) to discuss and vote on strategies to guide the USP's operations over the next five-year cycle.
the USPC conference, which coincides with the 200th anniversary of the USP this year, is only held as a remote meeting due to the COVID-19 outbreak.
meeting, USP Ceo Ron Piervincenzi detailed USP's progress in meeting the priorities set out in the 11 resolutions adopted at the 2015 USPC conference, which addressed key challenges at the time, including focusing on modernization, working more closely with USP stakeholders, and ensuring that USP growth and resource management and direction were more consistent.
He also described USP's achievements in working with the FDA over the past five years, including creating a pending monograph program, bringing together stakeholders to help mitigate opioid misuse and abuse through labeling and packaging standards, prioritizing quality standards for OTC drugs, such as products containing acetaminophen and testing for key impurities, and supporting the FDA's Drug Competition Action Plan (DCAP).
Piervincenzi stressed that for monographs to be most effective, they must include the latest analytical methods and testing requirements that reflect the state of the industry.
he reports on USP's progress in modernizing its methodology among its more than 6,800 standards to promote common quality goals for global drugmakers, eliminate outdated technologies, provide the basis for manufacturing innovation, and ensure the most basic impurities are identified and removed from processes.
usP leadership describes the 2020-2025 strategy prior to this year's meeting, the USP Board of Directors approved the strategy for the 2020-2025 cycle.
Piervincenzi explains how the new Impact Strategy will guide USP in its public health mission over the next five years and beyond.
In developing the strategy, USP considered the global public health landscape and sought to identify problems such as vulnerabilities in the global drug supply chain, increasing digitization of healthcare, advances in manufacturing and analytics technologies, and the introduction of new classifications and new drugs.
the next five-year strategy will focus on standards, advocacy and capacity-building, as well as supporting the driving force of the strategy.
details about the strategy to members of the USP employee leadership team.
Executive Vice President and Chief Scientific Officer Jaap Venema explains that USP's goal is to be an authoritative source of quality standards, noting that the meaning of "authority" varies in every area, such as small molecules, biologics, dietary supplements, or foods.
highlighted the explosive growth of new science in the fields of complex drugs, biologics, digital therapy and precision medicine.
commented that USP's goal was to increase the relevance of its standards to maximize impact and help ensure high-quality products in these areas.
, senior vice president of global external affairs at the U.S. Department of Technology, said USP's advocacy is expected to be a global institutional leader in improving the quality of medicines.
framework, he provided several specific examples, including concerns about the quality of USP antimicrobial drugs, noting that evidence developed by the USP Quality Institute revealed a link between nonconforming drugs and antimicrobial resistance.
, senior vice president of global health at the U.S. Pharmacopoeia, said of capacity-building that the U.S. Pharmacopeia will be a leading service provider to improve patient health by promoting the availability of high-quality medicines.
she cites an improvement in oxytocin in collaboration with Nigerian regulators, combining USP standards, capacity-building and advocacy to help overcome high temperatures in the supply chain and improve the availability of quality products.
15 Priority Resolution Resolutions for the next five years are a unique aspect of the USP governance process, providing a formal and institutionalized channel for USP member organizations and other stakeholders to inform and guide USP's strategic direction at the beginning of each five-year cycle.
decisions are made by the USP Council and considered by the USP Board of Directors and the Committee of Experts.
then the resolution is reflected in the organization's policy and operational agenda and used to adjust and plan.
at the USP meeting, representatives of member organizations considered 15 proposed resolutions and made a total of 230 comments on them before and during public hearings.
include concerns about resolutions, some of which are considered to go beyond the core work of the USP or require too many resources to implement.
the USP Committee responded to those comments and amended six resolutions.
resolution focused on supporting medical innovations in digital, biological and advanced therapeutic areas, and highlighted the contribution that USP could make to the development and distribution of standards for cannabis products.
.